United Therapeutics (UTHR) Revenue & Revenue Breakdown
United Therapeutics Revenue Highlights
Latest Revenue (Y)
$2.33B
Latest Revenue (Q)
$748.90M
Main Segment (Y)
Tyvaso
Main Geography (Y)
UNITED STATES
United Therapeutics Revenue by Period
United Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.33B | 20.20% |
| 2022-12-31 | $1.94B | 14.88% |
| 2021-12-31 | $1.69B | 13.63% |
| 2020-12-31 | $1.48B | 2.38% |
| 2019-12-31 | $1.45B | -11.00% |
| 2018-12-31 | $1.63B | -5.65% |
| 2017-12-31 | $1.73B | 7.91% |
| 2016-12-31 | $1.60B | 9.08% |
| 2015-12-31 | $1.47B | 13.76% |
| 2014-12-31 | $1.29B | 15.36% |
| 2013-12-31 | $1.12B | 21.93% |
| 2012-12-31 | $916.08M | 23.26% |
| 2011-12-31 | $743.18M | 23.08% |
| 2010-12-31 | $603.83M | 63.26% |
| 2009-12-31 | $369.85M | 31.39% |
| 2008-12-31 | $281.50M | 33.45% |
| 2007-12-31 | $210.94M | 32.14% |
| 2006-12-31 | $159.63M | 37.71% |
| 2005-12-31 | $115.92M | 57.51% |
| 2004-12-31 | $73.59M | 37.96% |
| 2003-12-31 | $53.34M | 77.09% |
| 2002-12-31 | $30.12M | 425.50% |
| 2001-12-31 | $5.73M | 179.70% |
| 2000-12-31 | $2.05M | 412.31% |
| 1999-12-31 | $400.00K | 300.00% |
| 1998-12-31 | $100.00K | - |
United Therapeutics generated $2.33B in revenue during NA 2023, up 20.20% compared to the previous quarter, and up 142.98% compared to the same period a year ago.
United Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $748.90M | 4.76% |
| 2024-06-30 | $714.90M | 5.49% |
| 2024-03-31 | $677.70M | 10.25% |
| 2023-12-31 | $614.70M | 0.87% |
| 2023-09-30 | $609.40M | 2.16% |
| 2023-06-30 | $596.50M | 17.68% |
| 2023-03-31 | $506.90M | 3.13% |
| 2022-12-31 | $491.50M | -4.75% |
| 2022-09-30 | $516.00M | 10.52% |
| 2022-06-30 | $466.90M | 1.08% |
| 2022-03-31 | $461.90M | 11.25% |
| 2021-12-31 | $415.20M | -6.63% |
| 2021-09-30 | $444.70M | -0.40% |
| 2021-06-30 | $446.50M | 17.78% |
| 2021-03-31 | $379.10M | -1.51% |
| 2020-12-31 | $384.90M | 1.26% |
| 2020-09-30 | $380.10M | 5.00% |
| 2020-06-30 | $362.00M | 1.60% |
| 2020-03-31 | $356.30M | 14.53% |
| 2019-12-31 | $311.10M | -22.52% |
| 2019-09-30 | $401.50M | 7.47% |
| 2019-06-30 | $373.60M | 3.03% |
| 2019-03-31 | $362.60M | -4.93% |
| 2018-12-31 | $381.40M | -7.58% |
| 2018-09-30 | $412.70M | -7.15% |
| 2018-06-30 | $444.50M | 14.21% |
| 2018-03-31 | $389.20M | -16.25% |
| 2017-12-31 | $464.70M | 4.31% |
| 2017-09-30 | $445.50M | 0.20% |
| 2017-06-30 | $444.60M | 20.00% |
| 2017-03-31 | $370.50M | -9.41% |
| 2016-12-31 | $409.00M | 0.20% |
| 2016-09-30 | $408.20M | -1.07% |
| 2016-06-30 | $412.60M | 11.82% |
| 2016-03-31 | $369.00M | -8.86% |
| 2015-12-31 | $404.88M | 4.83% |
| 2015-09-30 | $386.22M | 11.25% |
| 2015-06-30 | $347.16M | 6.00% |
| 2015-03-31 | $327.50M | -5.44% |
| 2014-12-31 | $346.36M | 4.97% |
| 2014-09-30 | $329.95M | 2.21% |
| 2014-06-30 | $322.80M | 11.54% |
| 2014-03-31 | $289.40M | 0.13% |
| 2013-12-31 | $289.02M | -4.37% |
| 2013-09-30 | $302.23M | 7.70% |
| 2013-06-30 | $280.61M | 14.47% |
| 2013-03-31 | $245.14M | 0.54% |
| 2012-12-31 | $243.82M | 0.56% |
| 2012-09-30 | $242.47M | 7.49% |
| 2012-06-30 | $225.58M | 10.46% |
| 2012-03-31 | $204.21M | 4.63% |
| 2011-12-31 | $195.18M | -3.25% |
| 2011-09-30 | $201.74M | 9.79% |
| 2011-06-30 | $183.75M | 10.95% |
| 2011-03-31 | $165.62M | -0.52% |
| 2010-12-31 | $166.48M | -2.64% |
| 2010-09-30 | $170.98M | 24.36% |
| 2010-06-30 | $137.49M | 6.68% |
| 2010-03-31 | $128.88M | 18.32% |
| 2009-12-31 | $108.92M | 12.04% |
| 2009-09-30 | $97.22M | 15.76% |
| 2009-06-30 | $83.98M | 5.33% |
| 2009-03-31 | $79.73M | 5.10% |
| 2008-12-31 | $75.86M | 1.11% |
| 2008-09-30 | $75.03M | 9.45% |
| 2008-06-30 | $68.56M | 10.49% |
| 2008-03-31 | $62.05M | 3.59% |
| 2007-12-31 | $59.90M | - |
United Therapeutics generated $748.90M in revenue during Q3 2024, up 4.76% compared to the previous quarter, and up 125.55% compared to the same period a year ago.
United Therapeutics Revenue Breakdown
United Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Adcirca | $28.90M | $55.90M | $67.30M | $107.20M | - |
| Unituxin | $198.90M | $182.90M | $202.30M | $122.90M | $113.70M |
| Product and Service, Other | $11.80M | $13.80M | - | - | - |
| Tyvaso | $1.23B | $873.00M | $607.50M | - | - |
| Remodulin | $494.80M | $500.20M | $513.70M | $516.70M | $587.00M |
| Orenitram | $359.40M | $325.10M | $306.10M | $293.10M | $225.30M |
United Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Tyvaso (53.01%), Remodulin (21.26%), Orenitram (15.44%), Unituxin (8.55%), Adcirca (1.24%), and Product and Service, Other (0.51%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remodulin | $128.30M | $147.30M | $128.00M | $115.10M | $131.10M | $127.20M | $121.40M | $122.50M | $114.00M | $132.00M | $131.70M | $118.30M | $125.40M | $139.80M | $130.20M | $127.90M | $124.50M | $119.00M | $145.30M | $107.40M |
| Unituxin | $61.10M | $51.70M | $58.40M | $54.20M | $51.30M | $44.30M | $49.10M | $36.70M | $46.10M | $44.50M | $55.60M | $50.00M | $55.30M | $53.10M | $43.90M | $29.70M | $37.60M | $29.00M | $26.60M | $33.60M |
| Tyvaso | $433.80M | $398.20M | $372.50M | $676.40M | $318.90M | $238.40M | $242.30M | $257.70M | $201.00M | $172.00M | $166.50M | $164.20M | $153.80M | $123.00M | $129.50M | $119.20M | $102.90M | - | - | - |
| Adcirca | $7.00M | $5.70M | $6.40M | $6.80M | $7.30M | $7.50M | $7.30M | $10.40M | $10.70M | $10.40M | $9.80M | $8.10M | $14.60M | $23.60M | $9.60M | $21.60M | $13.80M | $19.40M | $12.50M | $27.80M |
| Orenitram | $113.20M | $107.10M | $106.20M | $84.10M | $92.00M | $95.10M | $88.20M | $75.80M | $87.50M | $79.00M | $82.80M | $72.30M | $85.20M | $76.20M | $72.40M | $74.00M | $74.70M | $75.40M | $69.00M | $50.90M |
| Product and Service, Other | $5.50M | $4.90M | $6.20M | $3.90M | $1.90M | $3.50M | $2.50M | $3.80M | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | - | - | - | - | $516.00M | $466.90M | $451.90M | - | - | - | - | - | - | - | - | - |
United Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Tyvaso (57.92%), Remodulin (17.13%), Orenitram (15.12%), Unituxin (8.16%), Adcirca (0.93%), and Product and Service, Other (0.73%).
United Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $125.30M | $122.20M | $121.30M | - | - |
| UNITED STATES | $2.20B | $1.81B | $1.56B | $1.41B | - |
| European Union And Others | - | - | - | $71.20M | $125.60M |
| U | - | - | - | - | $1.32B |
United Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (94.62%), and Non-US (5.38%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $717.30M | $675.20M | $641.50M | $585.90M | $584.60M | $562.00M | $469.70M | $463.70M | $500.20M | $440.40M | $409.80M | $386.10M | $412.10M | $411.70M | $354.30M | $369.00M | $350.80M | - | - | - |
| Non-US | $31.60M | $39.70M | $36.20M | $28.80M | $24.80M | $34.50M | $37.20M | $27.80M | $15.80M | $26.50M | $52.10M | - | - | - | - | - | - | - | - | - |
| European Union And Others | - | - | - | - | - | - | - | - | - | - | - | - | $32.60M | $34.80M | $24.80M | $11.10M | $11.20M | $29.60M | $16.30M | $42.10M |
| U | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $326.70M | $294.80M | $359.40M |
United Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (95.78%), and Non-US (4.22%).
United Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $962.99M |
| BGNE | BeiGene | $2.46B | $929.17M |
| UTHR | United Therapeutics | $2.33B | $748.90M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| MNKD | MannKind | $198.96M | $66.26M |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| REPL | Replimune Group | - | - |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |
UTHR Revenue FAQ
What is United Therapeutics’s yearly revenue?
United Therapeutics's yearly revenue for 2023 was $2.33B, representing an increase of 20.20% compared to 2022. The company's yearly revenue for 2022 was $1.94B, representing an increase of 14.88% compared to 2021. UTHR's yearly revenue for 2021 was $1.69B, representing an increase of 13.63% compared to 2020.
What is United Therapeutics’s quarterly revenue?
United Therapeutics's quarterly revenue for Q3 2024 was $748.9M, a 4.76% increase from the previous quarter (Q2 2024), and a 22.89% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $714.9M, a 5.49% increase from the previous quarter (Q1 2024), and a 19.85% increase year-over-year (Q2 2023). UTHR's quarterly revenue for Q1 2024 was $677.7M, a 10.25% increase from the previous quarter (Q4 2023), and a 33.70% increase year-over-year (Q1 2023).
What is United Therapeutics’s revenue growth rate?
United Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 38.09%, and for the last 5 years (2019-2023) was 60.65%.
What are United Therapeutics’s revenue streams?
United Therapeutics's revenue streams in c 23 are Adcirca, Unituxin, Product and Service, Other, Tyvaso, Remodulin, and Orenitram. Adcirca generated $28.9M in revenue, accounting 1.24% of the company's total revenue, down -48.30% year-over-year. Unituxin generated $198.9M in revenue, accounting 8.55% of the company's total revenue, up 8.75% year-over-year. Product and Service, Other generated $11.8M in revenue, accounting 0.51% of the company's total revenue, down -14.49% year-over-year. Tyvaso generated $1.23B in revenue, accounting 53.01% of the company's total revenue, up 41.32% year-over-year. Remodulin generated $494.8M in revenue, accounting 21.26% of the company's total revenue, down -1.08% year-over-year. Orenitram generated $359.4M in revenue, accounting 15.44% of the company's total revenue, up 10.55% year-over-year.
What is United Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of United Therapeutics was Tyvaso. This segment made a revenue of $1.23B, representing 53.01% of the company's total revenue.